2026/2027
Elite AHIP
Certification
Test Bank:
Advanced
Medicare &
FWA Mastery
PART 0: THE NAVIGATOR
● Section 1: Foundational Syntax & Application (Questions 1–15)
○ Cognitive Focus: Deep definitional mastery of the 2026 Part D Redesign, Inflation
Reduction Act (IRA) Baseline Thresholds, and core Fraud, Waste, and Abuse
(FWA) mechanics.
● Section 2: Professional Simulation (Questions 16–40)
○ Cognitive Focus: Real-time Agent Compliance, Scope of Appointment (SOA)
, Execution, Medicare Prescription Payment Plan (M3P) Patient Interactions, and
Marketing Event transitions.
● Section 3: Grandmaster Synthesis (Questions 41–66)
○ Cognitive Focus: High-Stakes Multi-Variable Compliance, Catastrophic Phase
Computations, Complex FWA Evasion Tactics, and Dual-Eligible Special Needs
Plan (D-SNP) architectures.
PART I: THE PRIMER
Mastering the 2026/2027 Medicare landscape separates administrative order-takers from elite
compliance architects. Your ability to instantly synthesize the Inflation Reduction Act’s structural
changes with aggressive FWA enforcement will dictate your professional survival and high-level
success.
● The 2026 Hard Deck: The Part D Out-of-Pocket (OOP) maximum is strictly capped at
$2,100; the standard deductible is $615.
● The M3P Mandate: The Medicare Prescription Payment Plan smooths cash flow; it alters
the timing of payments, not total liability.
● The Compliance Baseline: All telephonic and virtual sales, marketing, and enrollment
calls must be recorded. Scope of Appointment (SOA) requires a 48-hour cooling-off
period unless a specific, statutory exception applies.
● The SSBCI Guardrails: Supplemental benefits for the chronically ill strictly exclude
cosmetic procedures, life insurance, and non-healthy food.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: Under the 2026 Medicare Part D benefit redesign implemented by the Inflation Reduction
Act (IRA), what is the MAXIMUM annual out-of-pocket (OOP) spending threshold for a
beneficiary? A) $2,000 adjusted solely for inflation B) $2,100 based on the annual percentage
increase in average expenditures C) $2,400 as proposed for the 2027 advance notice D) $8,000
before catastrophic coverage begins
● The Answer: B ($2,100 based on the annual percentage increase in average
expenditures)
● Distractor Analysis:
○ A is incorrect: $2,000 was the original 2025 cap, which adjusts annually based on
expenditure trends, not general inflation.
○ C is incorrect: $2,400 is the projected, proposed cap for 2027, not the finalized
2026 standard.
○ D is incorrect: $8,000 was the catastrophic threshold under legacy, pre-IRA
frameworks.
The Mentor's Analysis: The $2,100 hard cap is the foundational pillar of 2026 Part D
economics. Your professional intuition must immediately recognize that once a client hits this
number, cost-sharing drops to zero. Always anchor your plan comparisons on how quickly a
client’s specific formulary drives them to this $2,100 ceiling.
Q2: A client reviewing a 2026 stand-alone Prescription Drug Plan (PDP) asks about the initial
deductible. What is the STATUTORY MAXIMUM allowable Part D deductible for the 2026 plan
, year? A) $545 B) $590 C) $615 D) $2,100
● The Answer: C ($615)
● Distractor Analysis:
○ A is incorrect: $545 is a legacy deductible from 2024.
○ B is incorrect: $590 is the legacy deductible from 2025.
○ D is incorrect: This is the OOP maximum, not the deductible limit.
The Mentor's Analysis: Deductibles are a primary friction point in sales. Knowing the 2026
ceiling is $615 allows you to evaluate whether a plan offering a $0 deductible is compensating
for it with higher premiums or aggressive formulary tiering.
Q3: During the catastrophic coverage phase of the 2026 Part D benefit, what is the PRECISE
cost-sharing percentage for the enrollee? A) 0% B) 5% C) 20% D) 25%
● The Answer: A (0%)
● Distractor Analysis:
○ B is incorrect: 5% was the legacy enrollee liability before the IRA reforms fully
eliminated catastrophic cost-sharing.
○ C is incorrect: 20% is the CMS reinsurance subsidy amount for applicable drugs,
not the enrollee's share.
○ D is incorrect: 25% is the enrollee's coinsurance during the initial coverage phase,
prior to the OOP cap.
The Mentor's Analysis: The elimination of catastrophic cost-sharing is the most aggressive
financial protection in the modern Medicare era. When advising high-utilization clients, pivot the
conversation away from standard copays and strictly focus on the trajectory to reach the
catastrophic phase.
Q4: A beneficiary requires a monthly supply of a covered insulin product. Under 2026 CMS
guidelines, what is the MAXIMUM allowable copayment the enrollee will pay for a one-month
supply? A) $0 for all diabetic supplies B) $35 flat fee without exception C) 25% of the negotiated
price regardless of the total D) The lesser of $35 or 25% of the maximum fair price
● The Answer: D (The lesser of $35 or 25% of the maximum fair price)
● Distractor Analysis:
○ A is incorrect: $0 applies to recommended adult vaccines, not insulin.
○ B is incorrect: While $35 is the widely known cap, the statutory definition protects
the enrollee further if 25% of the negotiated/fair price is lower than $35.
○ C is incorrect: This ignores the hard $35 ceiling enacted by the IRA.
The Mentor's Analysis: Elite agents don't just memorize the "$35 rule"; they understand the
"lesser of" mechanic. If the drug's negotiated price drops significantly, the client's cost drops
below $35. Precision in statutory definitions prevents compliance complaints.
Q5: The Medicare Prescription Payment Plan (M3P) is a mandatory offering for all Part D
sponsors in 2026. Which statement BEST defines its core function? A) It reduces the total
annual out-of-pocket prescription liability for the beneficiary. B) It automatically enrolls
beneficiaries who exceed $615 in initial monthly drug costs. C) It allows enrollees to pay
out-of-pocket costs in capped monthly installments rather than at the point of sale. D) It provides
a secondary subsidy for clients who do not qualify for Extra Help.
● The Answer: C (It allows enrollees to pay out-of-pocket costs in capped monthly
installments rather than at the point of sale.)
● Distractor Analysis:
○ A is incorrect: M3P alters cash flow; it does not lower total liability or the $2,100
OOP cap.
○ B is incorrect: Enrollment is strictly an opt-in process; it is never automatic for new
Elite AHIP
Certification
Test Bank:
Advanced
Medicare &
FWA Mastery
PART 0: THE NAVIGATOR
● Section 1: Foundational Syntax & Application (Questions 1–15)
○ Cognitive Focus: Deep definitional mastery of the 2026 Part D Redesign, Inflation
Reduction Act (IRA) Baseline Thresholds, and core Fraud, Waste, and Abuse
(FWA) mechanics.
● Section 2: Professional Simulation (Questions 16–40)
○ Cognitive Focus: Real-time Agent Compliance, Scope of Appointment (SOA)
, Execution, Medicare Prescription Payment Plan (M3P) Patient Interactions, and
Marketing Event transitions.
● Section 3: Grandmaster Synthesis (Questions 41–66)
○ Cognitive Focus: High-Stakes Multi-Variable Compliance, Catastrophic Phase
Computations, Complex FWA Evasion Tactics, and Dual-Eligible Special Needs
Plan (D-SNP) architectures.
PART I: THE PRIMER
Mastering the 2026/2027 Medicare landscape separates administrative order-takers from elite
compliance architects. Your ability to instantly synthesize the Inflation Reduction Act’s structural
changes with aggressive FWA enforcement will dictate your professional survival and high-level
success.
● The 2026 Hard Deck: The Part D Out-of-Pocket (OOP) maximum is strictly capped at
$2,100; the standard deductible is $615.
● The M3P Mandate: The Medicare Prescription Payment Plan smooths cash flow; it alters
the timing of payments, not total liability.
● The Compliance Baseline: All telephonic and virtual sales, marketing, and enrollment
calls must be recorded. Scope of Appointment (SOA) requires a 48-hour cooling-off
period unless a specific, statutory exception applies.
● The SSBCI Guardrails: Supplemental benefits for the chronically ill strictly exclude
cosmetic procedures, life insurance, and non-healthy food.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: Under the 2026 Medicare Part D benefit redesign implemented by the Inflation Reduction
Act (IRA), what is the MAXIMUM annual out-of-pocket (OOP) spending threshold for a
beneficiary? A) $2,000 adjusted solely for inflation B) $2,100 based on the annual percentage
increase in average expenditures C) $2,400 as proposed for the 2027 advance notice D) $8,000
before catastrophic coverage begins
● The Answer: B ($2,100 based on the annual percentage increase in average
expenditures)
● Distractor Analysis:
○ A is incorrect: $2,000 was the original 2025 cap, which adjusts annually based on
expenditure trends, not general inflation.
○ C is incorrect: $2,400 is the projected, proposed cap for 2027, not the finalized
2026 standard.
○ D is incorrect: $8,000 was the catastrophic threshold under legacy, pre-IRA
frameworks.
The Mentor's Analysis: The $2,100 hard cap is the foundational pillar of 2026 Part D
economics. Your professional intuition must immediately recognize that once a client hits this
number, cost-sharing drops to zero. Always anchor your plan comparisons on how quickly a
client’s specific formulary drives them to this $2,100 ceiling.
Q2: A client reviewing a 2026 stand-alone Prescription Drug Plan (PDP) asks about the initial
deductible. What is the STATUTORY MAXIMUM allowable Part D deductible for the 2026 plan
, year? A) $545 B) $590 C) $615 D) $2,100
● The Answer: C ($615)
● Distractor Analysis:
○ A is incorrect: $545 is a legacy deductible from 2024.
○ B is incorrect: $590 is the legacy deductible from 2025.
○ D is incorrect: This is the OOP maximum, not the deductible limit.
The Mentor's Analysis: Deductibles are a primary friction point in sales. Knowing the 2026
ceiling is $615 allows you to evaluate whether a plan offering a $0 deductible is compensating
for it with higher premiums or aggressive formulary tiering.
Q3: During the catastrophic coverage phase of the 2026 Part D benefit, what is the PRECISE
cost-sharing percentage for the enrollee? A) 0% B) 5% C) 20% D) 25%
● The Answer: A (0%)
● Distractor Analysis:
○ B is incorrect: 5% was the legacy enrollee liability before the IRA reforms fully
eliminated catastrophic cost-sharing.
○ C is incorrect: 20% is the CMS reinsurance subsidy amount for applicable drugs,
not the enrollee's share.
○ D is incorrect: 25% is the enrollee's coinsurance during the initial coverage phase,
prior to the OOP cap.
The Mentor's Analysis: The elimination of catastrophic cost-sharing is the most aggressive
financial protection in the modern Medicare era. When advising high-utilization clients, pivot the
conversation away from standard copays and strictly focus on the trajectory to reach the
catastrophic phase.
Q4: A beneficiary requires a monthly supply of a covered insulin product. Under 2026 CMS
guidelines, what is the MAXIMUM allowable copayment the enrollee will pay for a one-month
supply? A) $0 for all diabetic supplies B) $35 flat fee without exception C) 25% of the negotiated
price regardless of the total D) The lesser of $35 or 25% of the maximum fair price
● The Answer: D (The lesser of $35 or 25% of the maximum fair price)
● Distractor Analysis:
○ A is incorrect: $0 applies to recommended adult vaccines, not insulin.
○ B is incorrect: While $35 is the widely known cap, the statutory definition protects
the enrollee further if 25% of the negotiated/fair price is lower than $35.
○ C is incorrect: This ignores the hard $35 ceiling enacted by the IRA.
The Mentor's Analysis: Elite agents don't just memorize the "$35 rule"; they understand the
"lesser of" mechanic. If the drug's negotiated price drops significantly, the client's cost drops
below $35. Precision in statutory definitions prevents compliance complaints.
Q5: The Medicare Prescription Payment Plan (M3P) is a mandatory offering for all Part D
sponsors in 2026. Which statement BEST defines its core function? A) It reduces the total
annual out-of-pocket prescription liability for the beneficiary. B) It automatically enrolls
beneficiaries who exceed $615 in initial monthly drug costs. C) It allows enrollees to pay
out-of-pocket costs in capped monthly installments rather than at the point of sale. D) It provides
a secondary subsidy for clients who do not qualify for Extra Help.
● The Answer: C (It allows enrollees to pay out-of-pocket costs in capped monthly
installments rather than at the point of sale.)
● Distractor Analysis:
○ A is incorrect: M3P alters cash flow; it does not lower total liability or the $2,100
OOP cap.
○ B is incorrect: Enrollment is strictly an opt-in process; it is never automatic for new
